From Nasdaq: 2025-05-08 18:11:00

Insulet Corporation reported a net income of $35.4 million for the first quarter of 2025, down from $51.5 million in the previous year. Earnings per share also decreased to $0.50 from $0.73, with the decline attributed to a $39.5 million loss on extinguishment of debt. However, revenue increased by 29 percent to $569.0 million, driven by growth in its Omnipod insulin delivery systems. Operating income and gross profit also saw significant increases. Insulet Corporation’s stock closed at $257.00 on Thursday, down 2.77 percent on the Nasdaq.



Read more at Nasdaq: Insulet Posts Mixed Q1 Results With Revenue Growth And Lower Earnings